Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Racemoramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemoramide SCHEMBL548434 | 0.94 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| Racemoramide SCHEMBL25463 | 0.94 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| Levomoramide SCHEMBL907811 | 0.94 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| Racemoramide SCHEMBL7474188 | 0.92 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| SCHEMBL9917087 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| SCHEMBL9917086 | 0.83 | KDM4E (0.46) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| SCHEMBL22313199 | 0.83 | L3MBTL1 (0.52) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| Racemoramide SCHEMBL8741247 | 0.81 | ADRA2B (0.44) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| SCHEMBL17028079 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 | |
| SCHEMBL22313196 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043613-A1 | SOLID FORM | FMC CORPORATION (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080311162-A1 | Solid form | FMC CORPORATION | 2008-12-18 | — | — | US | claimed |
| US-20080286343-A1 | Solid form | FMC CORPORATION | 2008-11-20 | — | — | US | claimed |
| WO-2008140460-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008140459-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008140461-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| US-20080286344-A1 | Solid form | FMC CORPORATION | 2008-11-20 | — | — | US | claimed |
| WO-2008008120-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-01-17 | — | — | WO | claimed |
| US-20080014228-A1 | Solid form | FMC CORPORATION | 2008-01-17 | — | — | US | claimed |
| CN-122032619-A | Catalyst for synthesizing tetrahydropyrrole by hydrofuran amination and preparation method and application thereof | 中国石油大学(华东) | 2026-05-15 | — | — | CN | disclosed |
| US-20250281680-A1 | DRUG-ELUTING SURGICAL ARTICLES AND RELATED METHODS | BIOSAPIEN INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250177290-A1 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | BioSapien Inc. | 2025-06-05 | — | — | US | disclosed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4522238-A2 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | Biosapien Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2000025757-A1 | SUSTAINED RELEASE DELIVERY OF HIGHLY WATER-SOLUBLE COMPOUNDS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-6004577-A | DELIVERING THERAPUETIC AGENT THROUGH BODY SURFACE USING ELECTROTRANSPORT BY PLACING SOLUTION COMPIRSING THERAPUETIC AGENT AND METAL COMPOUND CAPABLE OF COMPOLEXING WITH POLYBASIC ANION | ALZA CORPORATION | 1999-12-21 | — | — | US | disclosed |
| CN-1222093-A | Improved electrotransport of therapeutic agents containing polyanionic counterions | ALZA CORP (US) | 1999-07-07 | — | — | CN | disclosed |
| EP-0910432-A1 | ENHANCED ELECTROTRANSPORT OF THERAPEUTIC AGENTS HAVING POLYBASIC ANIONIC COUNTER-IONS | ALZA CORPORATION (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0609961-B1 | Sustained release pharmaceutical composition | FAULDING F H & CO LTD (AU) | 1998-06-24 | — | — | EP | disclosed |
| WO-1997047354-A1 | ENHANCED ELECTROTRANSPORT OF THERAPEUTIC AGENTS HAVING POLYBASIC ANIONIC COUNTER-IONS | ALZA CORPORATION (US) | 1997-12-18 | — | — | WO | disclosed |